Introduction
Zaher Nahie graduated in May 2003 and so no additional work has been conducted using funding from this grant [note that the funding has been put on hold pending a replacement]. Zaher has continued his role as a postdoc. Some of the work Zaher conducted while paid by this Army Breast Cancer fellowship has come to fruition, and will be published shortly. Therefore, the purpose of this summary is to provide an update as to the status of this project.
Body
Zaher's research proposal was centered on microarray studies that used the adenovirus E1A oncoprotein to probe the relationship between proliferation and apoptosis in human cells. During the course of his studies, Zaher identified the mitotic checkpoint gene Mad2 as a gene upregulated by E1A on his microarrays.
Intrigued by this result, Zaher went on to show that Mad2 was a direct target of E2F, using much the same methodology he used to identify caspases as E2F targets in his Nature Cell Biology paper. He also showed that, consistent with an E2F target, Mad2 is a cell cycle regulated gene. However, in contrast to many other E2F regulated genes, Mad2 is expressed primarily in mitosis. Importantly, in collaboration with Eva Hernando, a postdoc in Carlos Cordon-Cardo's lab at Memorial Sloan Kettering Cancer Center, Zaher showed that disruption of the Rb pathway and deregulation of E2F produced aberrantly high levels of Mad2, which are misexpressed throughout the cell cycle. Thus, E2F couples cell cycle progression to both apoptosis and mitotic control.
Asking whether Mad2 regulation would correlate with Rb defects in human cancers, Zaher worked with Drs. Hernando and Cordon-Cardo to show that Mad2 is overexpressed in retinoblastomas (which invariably have lost Rb function) and other cancers. In neuroblastoms, high Mad2 correlated with high E2F activity, and indeed, was a strong predictor of patient prognosis. Interestingly, high Mad2 expression also correlates with poor prognosis in breast cancer.
Zaher found it paradoxical that Mad2, a protein that facilitates proper checkpoint responses, was overexpressed in cells with Rb mutations, which often display chromosome instability. He therefore embarked on a series of experiments to test whether high Mad2 might alter mitotic events and be casually related to the chromosomal instability occurring in Rb deficient cells. Working with Dr. Hernando, he completed a series of elegant experiments showing that, indeed, elevated Mad2 was both necessary and sufficient to produce the genomic instability and aneuploidy observed in Rb deficient cells. These effects appear to result from the fact that Mad2 produces a hyperactive spindle checkpoint that ultimately becomes uncoupled from mitotic events.
The data suggests that aberrant expression of Mad2 arising as a result of Rb pathway defects can produce a hyperactive spindle checkpoint, thereby altering the sequence of mitotic and the accuracy of chromosome transmission. As a consequence, Mad2 expression contributes to mitotic alterations and chromosome instability in the context of an altered Rb/E2F pathway. They also illustrate how aneuploidy in human cancers can arise as a byproduct of the Rb pathway defects that occur during tumorigenesis. During normal cell proliferation, the cell cycle is hardwired to the spindle checkpoint via E2F, presumably to ensure that Mad2 is tightly controlled. As a consequence, mutations that disrupt Rb function produce deregulated E2F activity leading to inappropriate proliferation, but also aberrant Mad2 expression and, eventually, aneuploidy. Hence, the results provide one explanation for why loss-of-function mutations in spindle checkpoint genes are uncommon in human cancers. This model also implies that aneuploidy is not necessarily a selected trait of cancer cells but can be an inadvertent consequence of the uncontrolled proliferation that uncouples mitotic control from normal cell cycle progression. Nevertheless, this byproduct of Rb loss might subsequently increase the mutation rate, thereby fueling further tumor evolution.
We believe that our results on Mad2 and E2F provide a new model for the emergence of aneuploidy in human cancer, which has been associated with progression and poor prognosis in breast and other cancers. The manuscript describing these results was recently accepted for publication in Nature, with Zaher as co-first author. The manuscript acknowledges his support from the DOD-BCRP.
Key Accomplishments
Showed that Mad2 is a direct target of E2F and is a cell cycle regulated gene Demonstrated that deregulation of E2F produces aberrantly high levels of Mad2, which are misexpressed throughout the cell cycle Identified that Mad2 is overexpressed in retinoblastomas and other cancers Showed that elevated Mad2 is both necessary and sufficient to produce the genomic instability and aneuploidy observed in Rb deficient cells.
Reportable Outcomes
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Conclusion
letters to nature scription factors leading to uncontrolled cell cycle progression 3 . ' . APC/ harbour cells with abnormal chromosome numbers" 2 . However, cyclosome function is required for sister chromatid separation and the molecular defects underlying this trait, and whether they are cytokinesis 7 . Although mitotic checkpoint defects are often a cause or a consequence of the malignant phenotype, are not observed in cancer cells challenged with microtubule poisons, and dear. Mutations that disable the retinoblastoma (Rb) pathway inactivation of checkpoint components produces aneuploidy in are also common in human cancers'. These mutations promote yeast and mammalian cells"-*, loss-of-function mutations in spindle tumour development by deregulating the E2F family of tran-checkpoint genes are rarely observed in human tumours" . 
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-- 5 using an E2F-1 specific antibody in vector-(V) and ElA f, Immunoblotting for Mad2 in IMR90 cells synchronized in S phase and released from a (E)-expressing IMR90 cells. Duplex PCR amplifications were performed using primers double-thymidine blockade. Histone H3-P is shown as a marker of mitosis. g, Mad2 surrounding the putative E2F sites in the Mad2 promoter or the known sites in the cyclin A expression by LSC in NIH-3T3 cells, where the gate represents the threshold considered promoter, along with primers capable of amplifying Cyclin A genomic sequence (STS) positive for Mad2 based on the equivalent isotype control (Inset). (Fig. la, Many E2F targets are cell-cycle regulated'. Therefore, we examcompare lanes 1 and 2 or 3 and 4, respectively). Similarly, MEFs ined the cell cycle distribution of Mad2 expression in normal isolated from Rb-1-mice displayed increased Mad2 levels com-synchronously and asynchronously cycling cells. The level of pared to Rb+l+ controls (Fig. la, compare lanes 5 and 6) . IMR90 Mad2 was undetectable in quiescent IMR90 cells (Fig. le, t = 0) human fibroblasts expressing either EIA (Fig. lb, compare lanes 1 and increased after cells entered S phase following serum addition, and 2) or E2F-1 (Fig. lb, compare lanes 1 and 3) also expressed reaching maximum levels in G2/M, albeit slightly after cyclin A. The elevated Mad2 levels, implying that deregulation of the Rb/E2F increase in Mad2 was confined largely to mitosis, as assessed by copathway induces Mad2 through a conserved mechanism, expression with phosphorylated histone H3 following release from a The above results are consistent with the possibility that MAD2 is double-thymidine-induced S-phase arrest (Fig. If) , and by laser an E2F target. Concordantly, previous global chromatin immuno-scanning cytometry (LSC) analysis of Mad2 expression in unsynprecipitation/microarray studies suggested that E2Fs can bind the chronized NIH-3T3 fibroblasts (Fig. lg) . Presumably, Mad2 MAD2 promoter in normal fibroblasts". Indeed, analysis of the expression is regulated during the normal cell cycle as part of a MAD2 genomic sequence showed several putative E2F-binding sites mechanism that coordinates the expression of spindle checkpoint in the MAD2 promoter (see Supplementary Fig. S1 ), and sub-proteins with the onset of G2/M. sequent chromatin immunoprecipitation (ChIP) analysis con-E2F target genes are often constitutively expressed in cells with Rb firmed in vivo binding of E2F-1 to their predicted sites in EIA-pathway defects. Concordantly, Mad2 was expressed at aberrantly expressing cells (Fig. lc, lane 2) . Moreover, a genomic fragment high levels throughout the cell cyde in IMR90 cells expressing EIA containing the E2F sites ( Supplementary Fig. SI) conferred E2F (Fig. 2a) , which deregulates endogenous E2F, and in cells where Rb responsiveness to a luciferase reporter following transient transfec-was suppressed by stable RNA interference (RNAi) (shRb" 6 , Fig. 2a ). tion into IMR90 (data not shown) or U-20S cells (Fig. Id) in a Of note, Mad2 levels in EIA-and shRb-expressing IMR90 cells were manner comparable to the caspase-7 promoter, an established E2F similar to those produced by enforced expression of MAD2 (Fig. 2b , target'. Therefore, MAD2 is a physiological transcriptional target of c). As in normal fibroblasts, Mad2 was confined to G2/M in the E2F.
Rb-functional T24 bladder carcinoma" 7 Kendall tau correlation coefficient: 0.568; P < 0.0001) and valirespectively, Mad2 was expressed at high levels throughout the cell dated by immunohistochemistry (Fig. 3a, lower panels) . Moreover, cycle (Fig. 2d) . Thus, cells with Rb defects often aberrantly express aberrant Mad2 expression was associated with MYCN (a protoMad2. oncogene of the myelocytomatosis (MYC)-box genes) overexpresBecause the Rb pathway is frequently disrupted during tumori-sion and amplification (which can drive E2F constitutive actigenesis, we asked whether Mad2 is overexpressed in human tumour vation 2 ") and poor patient prognosis (Fig. 3c) . In fact, high Mad2 specimens. Retinoblastomas, which invariably lose Rb function and expression was more tightly associated with survival than MYCN deregulate E2F, expressed high levels of Mad2 relative to normal amplification (P = 0.001 for MAD2; P = 0.0215 for MYCN). Interretina (Fig. 3a, upper panels) . Similarly, Mad2 was significantly estingly, MAD2 also dusters with tens of genes capable of predicting increased in many bladder carcinomas when compared to normal disease outcome in breast cancer patientsu. Therefore, aberrant urothelium (data not shown), particularly in the more advanced Mad2 expression is linked to Rb pathway defects in human tumours, where Rb inactivation is common"' (Fig. 3a , middle tumours, where it can be an effective indicator of patient prognosis. panels). The elevated Mad2 levels observed in human tumours Most advanced human cancers are aneuploid, and loss of Rb were not merely due to the increased proliferation of cancer cells, as function has been associated with mitotic defects'. Hence, it is Mad2 was not always detected in highly proliferating normal and paradoxical that cells with defective Rb express higher levels of a tumour samples (see Supplementary Fig. S2 ).
protein that should facilitate proper checkpoint responses. We A clear link between deregulated E2F activity and aberrant Mad2 hypothesized that mis-expressed or elevated Mad2 might comproexpression was observed in neuroblastoma. Here, MAD2 messenger mise mitotic events, predisposing cells to genomic instability. RNA levels correlated tightly with E2F1 mRNA expression (an E2F Therefore, we examined the DNA content of IMR90 fibroblasts member but also a prototypical E2F target gene), as shown by expressingEIA, shRb or Mad2, all ofwhich expressed similarly high analysis of a microarray database containing information on 106 levels of Mad2 throughout the cell cycle (see Fig. 2 letters to nature LSC analysis comparing BrdU incorporation and DNA content chromosome instability, aberrant Mad2 activity is important for demonstrated that ElA-, shRB-and MAD2-transduced IMR90 or this process.
NIH-3T3 cell populations accumulated cells with greater than 4c
We suggest that aberrant expression of Mad2 arisingas a result of DNA content during the course of cell division (Fig. 4a) . These Rb pathway defects can produce a hyperactive spindle checkpoint, effects were exacerbated by treatment with nocodozole, which thereby altering the sequence of mitotic events and the accuracy of acutely engages the spindle checkpoint (data not shown).
chromosome transmission. Persistent inactivation of the APC/ Analogous results were obtained using fluorescent in situ hybrid-cydosome, mediated by Mad2 signalling, delays the degradation ization (FISH) to track specific chromosomes. The EIA-, shRB-and of securin and cycin B. Moreover, overexpression of securin (Pdsl, MAD2-expressing populations each accumulated cells with aber-PTTG)-observed in many different tumour types-produces aneurant chromosome numbers (Fig. 4b, c) . In contrast, IMR90 cells ploidy and displays transforming activity in vivo and in vitro 2 ". expressing a control vector retained normal chromosome content Interestingly, the behaviour of cells with aberrant Mad2 expression upon serial passaging (Fig. 4a-c , see Vector or V) and responded is reminiscent of cells treated for prolonged periods with nocodonormally to nocodazole (data not shown). Chromosome counting zole-following spindle checkpoint activation, these cells eventually of metaphase spreads confirmed that IMR90 and HCTl 16 cells with adapt and enter the next cell cycle without a proper mitosis 2 ". defective Rb or elevated Mad2 are frequently aneuploid (Fig. 4c) . Together, our results demonstrate that deregulated Mad2 expression No centrosome amplification was detected in EIA-or MAD2-contributes to mitotic alterations and chromosome instability in the transduced fibroblasts by -y-tubulin (see Supplementary Fig. S3b ) context of an altered Rb/E2F pathway. or 03-tubulin immunofluorescence staining (spindle shape analysis;
Our data illustrate how aneuploidy in human cancers can arise as data not shown), suggesting that the observed mitotic defects are a byproduct of the Rb pathway defects that accompany tumorigennot due to the effects of cydin E on centrosome duplication 24 ... esis. During normal cell proliferation, the cell cycle is hardwired to However, as cyclin E is an E2F target, centrosome amplification may the spindle checkpoint through E2F, presumably to ensure that exacerbate the chromosomal instability associated with Rb loss. Mad2 expression is tightly controlled. As a consequence, mutations Nevertheless, mis-expression of Mad2 is sufficient to produce this that disrupt Rb function produce deregulated E2F activity leading phenotype.
to inappropriate proliferation, but also aberrant Mad2 expression We next examined mitotic progression of individual cells in ElA-, and, eventually, aneuploidy. Hence, our results provide one explashRb-, MAD2-or vector-transduced populations co-expressing nation for why loss-of-function mutations in spindle checkpoint green fluorescent protein (GFP)-tagged histone (H2B-GFP), by genes are uncommon in human cancers' 1"2. Our model also implies phase contrast and fluorescence videomicroscopy. Whereas normal that aneuploidy is not necessarily a selected trait of cancer cells but NIH-3T3 cells underwent an orderly and rapid mitosis, cells can be an inadvertent consequence of defects that uncouple mitotic expressing ElA or shRb took an unusually long time to finish the control from normal cell cycle progression. Nevertheless, this process, displaying marked difficulties in completing cytokinesis byproduct of Rb loss might subsequently increase the mutation ( Fig. 5a-c; Supplementary Fig. S4a and S5 , compare video A with C rate, thereby fuelling further tumour evolution. 1] and D) and frequent defects in chromosome segregation ( Fig. 5c ; Supplementary Fig. S5, compare were also observed in EIA-, shRb-and MAD2-transduced HCT1 16 (MSCV-shMAD2A or B)", shmurMAD2 (shRNA control, MSCV-shmurMAD2)" or ( Supplementary Fig. S5 , videos I and J). In each cell population, the MAD2cDNA (Babe-MAD2) and selected with puromycin (2sg ml rr ".Adenoviruses frequency of aberrant mitoses decayed after serial passaging, per-EIA, EPF-I and GFP control were used at a multiplicity of infection of 100 PFU cell 'as haps owing to lethality of cells with aberrant chromosome content described". Nocodazole (Sigma) was used at 200 nM and 400 nM for normal fibroblast or tumour cell lines, respectively.
and/or to cellular adaptation to elevated Mad2. Nevertheless, consistent with a prolonged mitosis, cells aberrantly expressing P Mt andRNA uzuxuhiio Mad2 displayed a delay in the degradation of securin and cydlin B Protein expression was assessed by immunoblotting using 30 j~g of total cell lysate". Blots ( Supplementary Fig. S4b, c Complete downregulation of Mad2 in cells with intact Rb &PC2 (ab-I, Neomarkers) or a-tubulin (B-5-1-2, Sigma). Anti-mouse, anti-rabbit produces aneuploidy after a premature anaphase 27 . However, if (Amersham) or anti-goat horseradish peroxidase (HRP) (Sigma) were used as secondary Mad2 upregulation contributes to chromosome instability, we antibodies and proteins were visualized using an ECL detection system (Amersham).
Mad2uprgultio cotriute to hroosoe istailiy, e "RNA levels were assessed by northern blotting using 101,g of total RNA".
reasoned that a partial suppression of Mad2 in Rb defective cells m would have the opposite effect-perhaps reducing the occurrence of LSC md FACS aneuploid cells. Therefore, we used stable RNAi to partially suppress Cells grown as monolayers on microscope-chamber slides were washed, fixed and Mad2 in control, E2F-or EIA-transduced HCT1 16 cells. Consistent incubated with the respective antibodies-,: hsmad2 (BD Biosciences); alpha-tubulin FITC with a previous report", stable expression of two independent conjugated (done DM IA) and -y-tubulin (Sigma); and anti-Rb (Pharmingen, BD Laboratories). Mouse IgG served as an isotype negative control. Cells were washed and short-hairpin RNAs (shMAD2) in cells with low Mad2 levels further incubated with FITC-conjugated rabbit anti-mouse F(ab' )2 or anti-rabbit (DAKO), then reduced Mad2 expression and increased the percentage of aneu-washed and incubated with 5 pgml ' ofpropidium iodide (Pl; Molecular Probes) and ploid cells (data not shown). In contrast, co-expression of shMAD2 0.1% RNaseA (Sigma) in PBSbefore measurement bylSC (CompuCyte)as indicated". A with E2F or E1A significantly reduced Mad2 to nearly normal levels minimum of 3,000 cells were analysed per slide as previously described".
Cell cycle analysis after low-serum synchronization of IMR90 cells was performed as (Fig. 5d , compare lanes 3 with 7 or 2 with 8) and reduced the previously described". Mitotic index was quantified by measuring MPM2 expression fraction of aneuploid cells (Fig. 5e, f) without affecting EIA or E2F-(anti-MPM2, Upstate Biotechnology) versus DNA content (Pl) by FACS". For BrdU 1 levels ( Supplementary Fig. S4d ). Cells coexpressing shMAD2 and incorporation assays, slide-grown cells were incubated in 10 pM BrdU (Sigma) for l h either E2F-1 or EIA were proliferating and showed simlar S phase 30 min (human cell lines) or 3 h (normal fibroblasts) immediately before collection. Cells were fixed with 80% ethanol overnight and incubated with FITC-conjugated anti-BrdU content compared to cells harbouring a control shRNA (data not antibody (Pharmingen, BD Laboratories). BrdU incorporation was measured by LSC, shown). Therefore, although other Rb targets may contribute to with the equivalent FITC-conjugated isotypic control as a baseline.
